Expertise in
4
conditions

Han Y. Liang

81-Meishan Road, 
Hefei, CN 
Expertise in
4
conditions
81-Meishan Road, 
Hefei, CN 

Overview

Han Liang practices practicing medicine in Hefei, China.

Liang is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Stomach Cancer, Gastrointestinal Stromal Tumor, Bronchogenic Cyst, Gastrectomy, and Lymphadenectomy.

They are actively involved in clinical research, co-authoring 413 peer reviewed articles and participating in 1 clinical trial.

Locations

81-Meishan Road, Hefei, 230032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer
A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer
Enrollment Status: Terminated
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: SHR-1701 Injection
Study Phase: Phase 2/Phase 3

413 Total Publications

Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
Journal: Annals of medicine
Published: July 17, 2026

Frequently Asked Questions about Han Y. Liang

Is Han Y. Liang a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Han Y. Liang is classified as an Distinguished expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Han Y. Liang participate in research or clinical trials?

Yes. Han Y. Liang has published 413 articles and abstracts on conditions like Stomach Cancer. You can view a list of Han Y. Liang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liang's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile